All issues
Predecessor
Volume 31, Issue 9
Displaying 1-6 of 6 articles from this issue
- |<
- <
- 1
- >
- >|
-
TAKEMI KOEDA, MASUZO ODAKI, TETSUTARO NIIZATO1978 Volume 31 Issue 9 Pages 525-527
Published: September 25, 1978
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSEffectso f fosfomycin-sodium (FOM-Nau) pon renal functions were studied with male rats.
1) After fasting for 24 hours, 25 ml/kg body weight of physiological saline were, orally administeerreeda fatnedr. reTspheec stuivbesleyq1 u6e0na nt udr i3n2a0tmi ogn/sk agm oof uFnOtsM a-tN 4a w hoeurers in tirnatperevriatlo wneearell dyae tdeMrmininisetde rtedi mmediatelyth o see no efFfeOcMtof- N a upon the urination amount.
2) After suspending, water supply for 2 days, 1,000 mg/kg of FOM-Na were intraperitoneally administered once a day for successive 2 days. On the 3rd day, 50ml/kg of dextran were intraperitonally administered, and one hour thereafter, 1,000mg/kgo f F ONT-Nwa ere intramuscularlya dministered to hind leg. Blood samples were collected the following day (suspension of water was con-ti nued until blood sample collection) to determine the BUN and UA in serum. FOM-Na wasf ound ekerting on reinforcing effect upon renal dysfunctions caused by dextran.View full abstractDownload PDF (453K) -
YASUHI UEDA, FUMIO MATSUMOTO, ATSUSHI SAITO, MASAAKI OHKOSHI, NOBUO KA ...1978 Volume 31 Issue 9 Pages 528-535
Published: September 25, 1978
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSPipemidic acid is a new antibacterial chemotherapeutic for oral use synthesized by Research and Development Piviiion of Dainippon Pharniaceutical Co., Ltd.(Japan), having pyridopyrirnidine, ringas basal structure similar to pkomidic acid.
This drug has an antibacterial spectrum chiefly against Gram-negative bacilli, and its characteristicis that the drug exhibits a strong antibacterial activity against, naliclixic acid- and piromidic acid-resistant bacteria, and its antibacterial activity is superior to carbenicillin against Pseudomonas deruskinosa.
The present authors have carried out the laboratory examinations withpipemidfc acid on its antibacterial activity, absorption, excretion and distribution, and the clinical evaluations of the drag have been performed on the urinary tract infections in the fields of internal medicine and urologyView full abstractDownload PDF (5129K) -
MASAYUKI SHIMIZU, YOKO ITO, SHIGERU NOMURA1978 Volume 31 Issue 9 Pages 536-538
Published: September 25, 1978
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
Clinicale ffect of gentamicinin jected intravenouIZUMI KUROKAWA, NAOKI HAYASHI, YUTAKA ITOGA, MASATSUGU SATO, YOSHIAKI ...1978 Volume 31 Issue 9 Pages 539-544
Published: September 25, 1978
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
MAHITO KAWASHIMA, TAKEHIKO TORISU1978 Volume 31 Issue 9 Pages 545-548
Published: September 25, 1978
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSTobramycin (TOB) concentration in the bone marrow of tibia was examined 1, 2, 3 and 4 hours after intramuscular injection of 60mg: TOB concentration in the bone marrow of tibia 1 hour after injection was 2.8±0.578μg/ml. Ratio to serum was 87.5%. TOB concentration in the bone marrow of tibia 2 hours after injection was 1.6±0.480μg/ml. Ratio to serum was 94.1%. TOB concentration in the bone marrow of tibia 3 hours after injection was 1.1±0.337μg/ml. Ratio to serum was 84.6%. TOB concentration in the bone marrow of tibia 4 hours after injection was 0.8±0.372μg/ml. Ratio to serum was 80.0%. Penetration capacity of TOB into the bone marrow of tibia was excellent.View full abstractDownload PDF (712K) -
NORIYUKI KAWABATA, YAEMON SHIRAHA, SUSUMU DOI, KOSHIRO UMEMURA, KEIICH ...1978 Volume 31 Issue 9 Pages 549-560
Published: September 25, 1978
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSFOM-Na was investigated on its distribution after a continuous intravenous drip infusion in 3 healthy adult volunteers, and its serum levels and urinary excretion were pharmacokinetically analyzed, while the excreted substance into urine was also analyzed with GC/MS. The results obtained are summarized as follows:
1. The distribution volume of FOM-Na in one-compartment open model was 0.183 L/kg, half life in human body 1.66 hours and renal clearance 0.0737 L/hr/kg.
2. With these pharmacokinetic constants, the mean values following various doses demonstrated almost equal irrespective of its dosage schedule, keeping an almost constant level in each individualtested.
3. The area under serum level-time curve was approximately 216-Eg-Ehr/ml per 1g (potency), and increased in proportion to an infused dose within the range of 1-6g (potency). Three consecutive administrations showed no trend of accumulation of the agent in the serum.
4. Urinary excretion of the agent was found to be very fast, and its recovery rate from urine within 10-11hours after the completion of an i.v. drip infusion was approximately 95-99%.
5. As a result of GC/MS on the substance excreted into urine, it was noted that FOM-Na was not metabolized in human body and excreted into urine in its original form.
6. There was seen no specific change in electrocardiogram during and/or after an intravenous drip infusion in 1hour of 2g (potency) FOM-Na dissolved in a 300ml 5% glucose solution.View full abstractDownload PDF (1427K)
- |<
- <
- 1
- >
- >|